Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

8.82
+0.52006.27%
Volume:133.04K
Turnover:1.14M
Market Cap:195.56M
PE:-4.04
High:8.87
Open:8.25
Low:8.22
Close:8.30
Loading ...

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

Simply Wall St.
·
03 Nov 2024

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com
·
01 Nov 2024

INmune Bio Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

INmune Bio Q3 EPS $(0.60) Misses $(0.50) Estimate

Benzinga
·
01 Nov 2024

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

THOMSON REUTERS
·
01 Nov 2024

INmune Bio Q3 Operating Expenses USD 12.286 Million

THOMSON REUTERS
·
01 Nov 2024

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

GlobeNewswire
·
01 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Oct 2024

INmune Bio Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
30 Oct 2024

INmune Bio to host webinar on cognitive testing using EMACC, CDR-SB

TIPRANKS
·
28 Oct 2024

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

GlobeNewswire
·
28 Oct 2024

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

GuruFocus.com
·
26 Oct 2024

INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases

Dow Jones
·
25 Oct 2024

INmune Bio announces publication of XPro1595 data in Cell Reports

TIPRANKS
·
25 Oct 2024

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

GlobeNewswire
·
25 Oct 2024

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

THOMSON REUTERS
·
24 Oct 2024